Cardionate is used across specific domains where additional symptomatic support is needed. It is considered relevant for a range of conditions, including stable Angina Pectoris, Chronic Heart Failure (CHF), and Chronic Cerebrovascular Disorders.

Managing Ischemic Symptoms and Chronic Heart Strain

This medication is generally used to help manage symptomatic discomfort in conditions characterized by periods of heightened symptoms. It supports patients during episodes of heightened discomfort by addressing symptoms linked to organ-specific functional stress. This use contributes to improved comfort during symptomatic periods and may assist with managing symptoms that create noticeable physiological strain during activity. A key aspect of its application is supportive relief for symptoms related to physical discomfort experienced during heart-related episodes.

Supporting Brain Circulation and Cognitive Function

Cardionate is considered relevant in conditions involving episodic or fluctuating manifestations, applied across domains where additional symptomatic support is needed to address symptoms that interfere with daily functioning, such as mild neurocognitive deficits. This assists with supporting general well-being during symptomatic phases when cognitive symptoms become more noticeable. It may also be used in conditions related to retinopathies and general systemic exhaustion.

Assisting Systemic Recovery and Overstress Symptoms

The medication is commonly used when short-term symptomatic assistance is needed in scenarios involving high physiological stress, such as periods of high physical or intellectual overstress or during periods requiring supportive management of post-episode discomfort. It helps address symptom clusters that may create noticeable physiological strain, and provides support that helps ease the overall symptom burden related to systemic exhaustion.

Quick Fact: Relief for Functional Strain Cardionate is used to help manage symptoms that create noticeable functional strain related to chronic heart and brain circulation issues, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. Substance Profile from the U.S. Anti-Doping Agency

The population eligibility for Cardionate is strictly defined by official regulatory documentation, centering on age, organ function, and reproductive status.

Populations Who Must Not Use Cardionate

Use is contraindicated (must not be used) in patients who have a known hypersensitivity to the active substance, Meldonium, or any of the product’s excipients. Furthermore, individuals with severe liver impairment or severe renal impairment are officially prohibited from using the medicine.

Age and Reproductive Restrictions

Cardionate use is restricted to the adult population (18 years and older). The medicine is not recommended for children and adolescents under 18 because safety and efficacy data have not been established in these age groups. For women, Cardionate is also not recommended during pregnancy or lactation (breastfeeding), as safety for the fetus or infant has not been confirmed in regulatory studies.

Conditional Eligibility

The official labeling also requires caution for patients with non-severe, chronic liver or renal diseases, and for elderly patients who present with concurrent organ impairment. These populations may be eligible but require special consideration as documented by regulatory authorities.

Interaction Map: Interactions with other medicines and products — official regulatory information for Cardionate

The regulatory profile for Cardionate details a documented pharmacodynamic interaction involving co-administration with other cardiovascular treatments. The official label does not document any pharmacokinetic (PK) interactions, such as those mediated by CYP enzymes or drug transporters, nor does it specify any required timing separation rules.

---

Interaction Scope

Field	Official Regulatory Findings
Medicinal product categories with documented interactions	Cardiovascular medicinal products (general class)
Specific interacting medicines	Glyceryl trinitrate, Nifedipine, Beta-adrenoblockers, Hypotensive agents, and Peripheral vasodilators
Mechanistic basis of interactions	Pharmacodynamic effect (Intensification of action)
Interaction-related restrictions	None explicitly classified as contraindicated due to drug-drug interaction risk.

Interaction Classifications (High-Level)

Field	Official Regulatory Classification
Interaction severity classification	Use-with-caution combination (Implied by warning of intensified action).
Regulatory basis	Summary of Product Characteristics (SmPC) issued by national health authorities.

---

Resulting Interaction Structure

Official interaction statements:

• The drug is formally stated to intensify the action of several cardiovascular function agents, specifically including those listed in the official label.
• Co-administration is formally noted as permitted with other cardiovascular classes, such as antianginal products, anticoagulants, antiarrhythmics, diuretics, and cardiac glycosides.
• No specific interactions with food, alcohol, or herbal products are documented in authoritative regulatory sources.
• No population-specific interaction cautions are included in the labeling for this section.

Connection to the overall interaction profile: The regulatory documents primarily define the product’s interaction structure through a single, documented pharmacodynamic outcome of potentiation with select cardiovascular agents. The official profile contains no explicit documentation of major pharmacokinetic interactions, mandatory dose-timing requirements, or formal prohibitions against combining agents.

Cardionate, containing the active substance Meldonium, functions as a metabolic modulator that re-engineers cellular energy production and confers cytoprotection when oxygen supply is low. The mechanism involves a sequence of molecular and cellular events.

1. Inhibition of L-Carnitine Synthesis

The mechanism begins by directly targeting the enzyme gamma-Butyrobetaine Hydroxylase (BBOX), acting as a competitive inhibitor. By restricting the synthesis of L-Carnitine, the drug controls the cofactor needed to transport fatty acids into the cell's mitochondria. This action restricts the cell’s utilization of a relatively oxygen-intensive process.

2. Metabolic Shift to Glucose Utilization

The resulting reduction in L-Carnitine limits the efficiency of Fatty Acid beta-Oxidation (FAO). As FAO slows, the cell compensates by upregulating the use of Glucose Oxidation (Glycolysis) for energy production. This metabolic shift is the key physiological action; glucose utilization yields more ATP per unit of oxygen consumed, resulting in increased oxygen efficiency.

3. ️ Cellular Cytoprotection under Stress

The optimized energy production helps maintain ATP homeostasis in high-demand tissues during conditions of ischemia (oxygen deficiency). Furthermore, the reduced reliance on fatty acid breakdown prevents the accumulation of potentially toxic intermediate metabolites. This dual action confers a state of cytoprotection, which involves preserving cell structure and function during metabolic stress.

Cardionate (Meldonium dihydrate) is administered according to a time-limited regimen. The medicine is available in two primary forms: hard capsules for oral use and a solution for intravenous administration. The standard usage pattern for adults involves a daily dose ranging from 500 mg to 1000 mg of meldonium dihydrate. This total daily amount may be administered as a single dose or divided into two doses for flexible scheduling.

The usage protocol involves taking the medication in the morning due to a specific procedural constraint related to its pharmacological action. The oral capsules are intended to be swallowed whole with water and may be taken with food to mitigate potential gastrointestinal discomfort. The overall use is structured as a defined treatment course that typically lasts 4 to 6 weeks.

Regarding specific patient populations, the medicine is not recommended for children due to insufficient data. However, lower doses may be required for older adults who have documented renal or hepatic impairment. This standardized protocol defines the method of administration.

Research evidence / Overview of studies for Cardionate

Evidence for Use in Stable Angina Pectoris

Research for stable angina involved short-term Randomized Controlled Trials (RCTs) and several meta-analyses that included settings where the study medicine was administered alongside standard care. These studies examined patient physical capacity, often measured using objective tests like exercise stress testing (total time spent and load achieved). They also applied in studies examining patient-reported experiences of physical discomfort, such as the reported frequency of episodic anginal attacks, and studies monitored specific heart function indices on ECG. The research included adult patients diagnosed with stable effort angina.

The findings describe patterns observed in the studies, such as measurements taken of physical performance during exercise tests. Some trials reported measurements related to the self-reported frequency of anginal symptoms over the short-term study period. The outcomes reviewed are typically derived from short observation periods.

Evidence for Use in Chronic Heart Failure (CHF)

Research examined short-term measurements related to symptoms in adult patients diagnosed with conditions marked by functional limitations, specifically Chronic Heart Failure (CHF). Studies primarily was evaluated in how patients' daily functioning or activity level changed, using standardized physical assessments like the 6-Minute Walk Test (measuring walking distance) and evaluating general functional class scales. They also applied in studies examining patient-reported experiences related to quality of life.

Studies reported how symptoms evolved in the observed populations, highlighting measured distance in the 6-Minute Walk Test. Researchers also described measurements taken related to functional classification of patients. The data are often derived from studies where the medicine was administered alongside existing background medications.

Long-term Follow-up and Durability of Study Findings

The research has focused primarily on short-term observation periods, typically up to three months, to evaluate outcomes reflecting daily functioning or activity level. While these studies provide context but not individual predictions about short-term changes, long-term effects are not fully established. Follow-up durations were limited, and the evidence does not provide substantial insight into the sustained maintenance of measured patterns beyond the study end dates. Ongoing research may further explore the long-term patterns.

Limitations and Research Uncertainty

It is important to understand that the overall evidence quality varies across studies. For most indications, sample sizes were modest, and comparative evidence is lacking for certain endpoints. The follow-up durations were limited, meaning there is limited information for long-term outcomes related to durability or sustained functional measurements. Furthermore, findings were mixed in some systematic reviews, and research is ongoing to fill these gaps. Evidence highlights what is known — and what is still uncertain.

Common questions about Cardionate (FAQ)

Q: Does Meldonium (Mildronate) interact with other medications, such as pain relievers (NSAIDs) or other chronic non-cardiovascular drugs?

Official product information indicates that Cardionate (Meldonium) may strengthen the effects of certain medicines used for cardiovascular conditions, such as nitroglycerin, nifedipine, and beta-blockers. Because of this potential for increased action, a dosage adjustment of these co-administered drugs is generally considered. Official product information does not include specific details regarding interactions with common non-prescription pain relievers like NSAIDs or other chronic non-cardiovascular drugs.

Q: How long can I safely take Meldonium for chronic conditions?

According to regulatory guidelines, the overall use of Cardionate is structured as a defined, time-limited treatment course. This course typically lasts between four to six weeks. Official documents describe repeated courses as possible, but this procedure is carried out only after a professional evaluation by a healthcare provider.

Q: Is Meldonium safe for elderly patients?

Official regulatory documents do not contain a specific general recommendation for the use of Cardionate in all older adults. However, the product information notes that dosage adjustments are a consideration for older patients who have documented issues with their liver or kidneys (hepatic and/or renal impairment).

How to Store and Dispose of Cardionate (Meldonium)

Required Storage Conditions

Official labeling requires that Cardionate be stored out of the sight and reach of children. The medicine must be kept in the original package to ensure protection from moisture and must not be stored above 25 °C. These conditions are necessary to maintain the product's quality and stability up to the expiry date listed on the container.

Disposal Instructions

Cardionate must not be disposed of using wastewater or general household waste. To prevent environmental contamination, official instructions mandate that unused or expired medicine should be returned for proper disposal. Patients should consult a pharmacist for the specific procedure on how to safely discard the medicine when it is no longer needed.